Samarium for osteoblastic bone metastases and osteosarcoma

被引：34
作者：
Anderson, Pete [1 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Dept Pediat, Houston, TX 77030 USA
来源：
EXPERT OPINION ON PHARMACOTHERAPY | 2006年 / 7卷 / 11期
关键词：
153Sm-EDTMP; bone cancer; bone metastases; bone scan; breast cancer; MIMvista fusion imaging software; osteosarcoma; prostate cancer; skeletal neoplasia; radiation therapy; radiopharmaceutical; radiosensitisation; sarnarium-153; lexidronam;
D O I：
10.1517/14656566.7.11.1475
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Samarium-153 lexidronam (Sm-153-EDTMP) is FDA approved for painful osteoblastic bone metastases that image on bone scan. Sm-153-EDTMP decay has a therapeutic p-emission and ay-photon for bone scan imaging. Monitoring of osteosarcoma radiation treatment effectiveness was performed with bone, CT, MRI and PET/CT fusion imaging. Bone scan and PET/CT improved in 5 out of 9 and 16 out of 18 osteosarcoma sites, respectively. Sm-153-EDTMP targets multiple sites of disease, with a single administration. Side effects of Sm-153-EDTMP (0.5 - 2.5 mCi/kg) have been minimal and include transient thrombocytopenia and neutropenia. 153Sm-EDTMP can be combined with radiation therapy, bisphosphonates and/or chemotherapy to synergistically improve palliation. This article reviews the rationale, indications and monitoring of standard-dose samarium and investigational high-dose Sm-153-EDTMP treatment of cancer involving bone.
引用
收藏
页码：1475 / 1486
页数：12
相关论文
共 107 条
  • [21] COLLINS C, 1993, J NUCL MED, V34, P1839
  • [22] Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer
    Crane, CH
    Janjan, NA
    Evans, DB
    Wolff, RA
    Ballo, MT
    Milas, L
    Mason, K
    Charnsangavej, C
    Pisters, PWT
    Lee, JE
    Lenzi, R
    Vauthey, JN
    Wong, A
    Phan, T
    Nguyen, Q
    Abbruzzese, JL
    [J]. INTERNATIONAL JOURNAL OF PANCREATOLOGY, 2001, 29 (01) : 9 - 18
  • [23] A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer
    Dafermou, A
    Colamussi, P
    Giganti, M
    Cittanti, C
    Bestagno, M
    Piffanelli, A
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2001, 28 (07) : 788 - 798
  • [24] deKlerk JMH, 1996, J NUCL MED, V37, P244
  • [25] Dickie G J, 1999, Australas Radiol, V43, P476, DOI 10.1046/j.1440-1673.1999.00716.x
  • [26] Bisphosphonates for controlling pain from metastatic bone disease
    Diener, KM
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1996, 53 (16) : 1917 - 1927
  • [27] A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma
    Dispenzieri, A
    Wiseman, GA
    Lacy, MQ
    Litzow, MR
    Anderson, PM
    Gastineau, DA
    Tefferi, A
    Inwards, DJ
    Micallef, INM
    Ansell, SM
    Porrata, L
    Elliott, MA
    Lust, JA
    Greipp, PR
    Rajkumar, SV
    Fonseca, R
    Witzig, TE
    Erlichman, C
    Sloan, JA
    Gertz, MA
    [J]. LEUKEMIA, 2005, 19 (01) : 118 - 125
  • [28] Dormehl IC, 1998, ARZNEIMITTEL-FORSCH, V48, P408
  • [29] Pathophysiology of bone metastases from prostate cancer and the role of bisphosphonates in treatment
    Eaton, CL
    Coleman, RE
    [J]. CANCER TREATMENT REVIEWS, 2003, 29 (03) : 189 - 198
  • [30] EISENHUT M, 1986, J NUCL MED, V27, P1255
12345678910